Skip to main content
. 2020 Sep 4;142(17):1623–1632. doi: 10.1161/CIRCULATIONAHA.120.047480

Figure 2.

Figure 2.

Effect of dapagliflozin versus placebo on manifestations of worsening heart failure. Hazard ratios and 95% CIs were estimated with the use of Cox regression models, stratified according to diabetes status, with a history of hospitalization for heart failure and treatment-group assignment as explanatory variables. CV indicates cardiovascular; and HF, heart failure.